|
7 . Курение является причиной 90?% всех случаев рака легких, являющегося одним из самых агрессивных видов злокачественного процесса. Прекращение курения является самым эффективным методом профилактики этого рака. Обычный рентген грудной клетки может быть простым и эффективным способом ранней диагностики рака легких. Список литературы (глава 12) 1. Tabar L, Vitak B, Chen TH, et al. Swedish two-country trial: impact of mammographic screening on breast cancer mortality during three decades . Radiology 2011, 260: 658–663. 2. Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: New genetic developments, new therapeutic avenues . Human Genetics 2008; 124(1): 31–42. 3. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104(12): 2807–16. 4. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2010 . Bethesda, MD: National Cancer Institute, Retrieved June 24, 2013. 5. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies . American Journal of Human Genetics 2003; 72(5): 1117–1130. 6. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance . Journal of Clinical Oncology 2007; 25(11): 1329–1333. 7. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. Journal of the National Cancer Institute 2002; 94(18): 1365–1372. 8. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296(2): 185–192. 9. http://www.ncbi.nlm.nih.gov/pubmed/168354249/ Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers . Journal of the National Cancer Institute 2007; 99(23): 1811–1814. 10. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers . British Journal of Cancer 2007; 96(1): 11–15. 11. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. Journal of Clinical Oncology 2009; 27(3): 433–438. 12. von Karsa L, Patnick J, Segnan N et al. European Colorectal Cancer Screening Guidelines Working Group 2013. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full dupplement publication. Endoscopy 2013; 45: 51–59. — 185 —
|